Eye to Market Episode 5: Formulation Best Practices for Ophthalmic Innovation

LEGAL DISCLAIMER*: This content is for informational purposes only and does not constitute legal, medical, regulatory, or financial advice. Eye to Market is a video series exploring how ophthalmic innovations move from concept to patient care. In Episode 5, experts discuss formulation best practices and the critical decisions that influence product stability, safety, efficacy, manufacturability, and commercialization. Topics include excipient selection, analytical validation, stability testing, sterile product development, scalability, patent considerations, and when innovators should engage a CDMO to support development and manufacturing. The conversation highlights why formulation is more than creating a product that works. It is about building a solution that can be consistently manufactured, tested, scaled, and delivered to patients successfully. Developed in collaboration between Eyecelerator, Ora, and Unither Pharmaceuticals, Eye to Market provides practical insights and real-world perspectives to support innovation across the ophthalmology ecosystem. 🎬 Watch more episodes in the Eye to Market playlist: [playlist link] Learn more about Eyecelerator: [website link] #EyeToMarket #Ophthalmology #FormulationDevelopment #HealthcareInnovation #Eyecelerator *The views and opinions expressed in this series are those of the individual participants and do not necessarily reflect those of Eyecelerator, Ora, Unither, or their affiliates. This content is provided for informational and educational purposes only and is not intended, and should not be relied upon, as legal, medical, regulatory, financial, or professional advice. Nothing herein constitutes an endorsement or an offer to buy or sell any securities. Viewers should consult qualified professionals regarding their specific circumstances before making any decisions.